| Literature DB >> 30936218 |
Abstract
Treatment with chimeric antigen receptor T cells has led to impressive and durable responses in adult and pediatric malignancies refractory to conventional therapy; however, only patients with a handful of cancers have responded thus far and significant disparities exist between the response rates of pediatric and adult patients. A new extensive analysis of pediatric patient T-cell subsets at diagnosis and throughout the patients' chemotherapy courses in a variety of solid and hematologic malignancies sheds new light on the intrinsic T-cell deficits that may be partly to blame.See related article by Das et al., p. 492. ©2019 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30936218 DOI: 10.1158/2159-8290.CD-19-0073
Source DB: PubMed Journal: Cancer Discov ISSN: 2159-8274 Impact factor: 39.397